MarketInOut Stock Screener Log In | Sign Up
 

Alto Neuroscience Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/23/2026
Alto Neuroscience Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization849.79 mln
Float35.61 mln
Earnings Date03/24/2027

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

38.88
Transformational upside

Relative Strength

11 / 100
Significantly lagging

Debt / Equity

0.11
Very low leverage

ROE

-49.63
Deeply negative

ROA

-41.30
Deeply negative

Business Description

Alto Neuroscience is a drug development company based in Mountain View, California, focused on creating new treatments for brain and mental health conditions. The company has several medications in various stages of clinical testing, targeting conditions such as bipolar depression, major depressive disorder, schizophrenia-related cognitive impairment, and Parkinson's disease. Founded in 2019, Alto Neuroscience is working to advance these experimental drugs through clinical trials toward potential approval and patient use.

Key Fundamentals

EPS-2.31
ROE-49.63
ROIC-676
ROA-41.30
Interest Cover19.66
EBITDA, mln-81.27
EV / EBITDA-12.38
EV / EBIT-12.28

Quote Details

Last 21.97
Change -0.23 (-1.04%)
Open 21.95
Volume 379,246
Turnover 8,332,034
Average Volume 666,140

Financial Ratios

Leverage Ratio1.16
Current Ratio14.85
Price / Book4.17
Price / Tangible Book4.17
Debt / Equity0.11

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price38.88
Short Ratio7.73
Short % of Float13.91

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.14% 53 / 100   
1 Month -19.17% 6 / 100   
2 Months -15.17% 14 / 100   
6 Months -10.4% 22 / 100   
1 Year 115% 99 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog